Merck & Co. and LaNova Medicines, a Shanghai-based bio/pharmaceutical company, have entered into an exclusive global license to develop, manufacture and commercialize LaNova Medicine’s LM-299, an investigational bispecific antibody from…
Otsuka, ICU Medical In Joint Venture for IV Solutions Supply
Otsuka Pharmaceutical Factory (OPF), a subsidiary of Otsuka Holdings, and ICU Medical, a medical device company, have formed a joint venture (JV) for IV solutions to serve the North American…
The latest from CDMOs, CMOs, and suppliers featuring Lonza, Avantor, Adragos Pharma, Gilero, Sekisui Cryoport and GenScript Biotech. Chemicals/Chemical API Manufacturing * Lonza To Expand Bioconjugation With Two New Mfg Suites Biologics…
Partnering News: Roche, Novo Nordisk, Ascendis & More
A roundup of bio/pharmaceutical partnering news from Roche/Flare Therapeutics, Novo Nordisk/Ascendis Pharma and Royalty Pharma/Syndax. * Roche, Flare Therapeutics In $1.8-Bn Small-Molecule Cancer Drug Pact* Novo Nordisk, Ascendis In $285-M+…
GHO Capital, Ampersand Capital To Acquire Avid Bio For $1.1 Bn
Two private equity firms, GHO Capital Partners and Ampersand Capital Partners, have agreed to acquire Avid Bioservices, a Tustin, California-based CDMO of biologics, for $1.1 billion. Avid’s services include cGMP…
SK bioscience Acquires Controlling Stake in IDT Biologika
SK bioscience, a Seongnam, South Korea-based vaccines and biologics company, has completed its acquisition of a 60% stake in IDT Biologika, a Dessau-Rosslau, Germany-based CDMO of viral vaccines, cell- and…
The latest from CDMOs, CMOs, and suppliers featuring Evotec, Fujifilm Diosynth Biotechnologies and Olon. Chemicals/Chemical API Manufacturing * Evotec To Sell Chemical API Mfg Facility To Investment Firm * Olon Provides Update…
A roundup of manufacturing news from Nektar and Accord Healthcare. Highlights below. * Nektar to Sell PEG Mfg Facility, Reagent-Supply Business for $90 M * Accord Healthcare Investing $65 M In…
GSK Investing $800 M in New US-Based Mfg Facilities
GSK has announced an up to $800 million investment to bring drug-substance manufacturing and additional drug-product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, making it the company’s largest…
AbbVie has agreed to acquire Aliada Therapeutics, a bio/pharmaceutical company focused on central nervous system diseases, for $1.4 billion. Aliada’s lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ)…
